Article

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infections

2022-02-21

Abstract excerpt

Bacillus Calmette-Guérin (BCG) is recommended as intravesical immunotherapy to reduce the risk of tumor recurrence in patients with non-muscle invasive bladder cancer (NMIBC). Currently, it is unknown whether intravesical BCG application induces trained immunity. Here, we found that intravesical BCG does induce trained immunity based on an increased production of TNF and IL-1β after heterologous ex-vivo stimulati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 97e98747-e1a0-5cb3-83e8-f537ffcb5066
DOI: 10.1101/2022.02.21.480081

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infectionsDOI 10.1101/2022.02.21.480081Read

Differential effects of BCG-Russia and BCG-TICE on trained immunity: potential implications for bladder cancer immunotherapySemantic proximity Read

Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studiesSemantic proximity Read

Lysine methyltransferase G9a is an important modulator of trained immunitySemantic proximity Read

Microbial cancer immunotherapy reprograms hematopoiesis to enhance anti-tumor immunitySemantic proximity Read

Current Understanding of Bacillus Calmette-Guérin-Mediated Trained Immunity and Its Perspectives for Controlling Intracellular InfectionsSemantic proximity Read

A single-cell view on host immune transcriptional response to in vivo BCG-induced trained immunitySemantic proximity Read

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity.Semantic proximity Read

Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.Semantic proximity Read

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.Semantic proximity Read

Elevated T-cell exhaustion and urinary tumor DNA levels are associated with BCG failure in patients with non-muscle invasive bladder cancerSemantic proximity Read

Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-Muscle-Invasive Bladder Cancer.Semantic proximity Read

Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity Read